Assessment of systolic function in the evaluation of patients with cirrhosis
Søren Møller, Jens D. Hove – 20 March 2017
Hepatitis C treatment threshold in patients with decompensated liver disease
Duminda Suraweera, Sammy Saab – 20 March 2017
Screening for hepatocellular carcinoma: A drug safety issue
Alain Braillon – 20 March 2017
Hepatitis C virus–induced CCL5 secretion from macrophages activates hepatic stellate cells
Reina Sasaki, Pradip B. Devhare, Robert Steele, Ranjit Ray, Ratna B. Ray – 20 March 2017 – Hepatitis C virus (HCV)–mediated chronic liver disease is a serious health problem around the world and often causes fibrosis/cirrhosis and hepatocellular carcinoma. The mechanism of liver disease progression during HCV infection is still unclear, although inflammation is believed to be an important player in disease pathogenesis. We previously reported that macrophages including Kupffer cells exposed to HCV induce proinflammatory cytokines.
Beyond sensing: Retinoic acid inducible gene‐I (RIG‐I) continues to expand its antiviral effector functions
Amy E.L. Stone, Michael J. Gale – 20 March 2017
Risks of proton pump inhibitors for patients with cirrhosis: The controversy remains
- Read more about Risks of proton pump inhibitors for patients with cirrhosis: The controversy remains
Ângelo Zambam de Mattos, Suelen Aparecida da Silva Miozzo, Cristiane Valle Tovo, Angelo Alves de Mattos – 20 March 2017
Reply
Kyle S. McCommis, Jerry R. Colca, Brian N. Finck – 20 March 2017
Statins decrease the risk of decompensation in hepatitis B virus– and hepatitis C virus–related cirrhosis: A population‐based study
Fu‐Ming Chang, Yen‐Po Wang, Hui‐Chu Lang, Chia‐Fen Tsai, Ming‐Chih Hou, Fa‐Yauh Lee, Ching‐Liang Lu – 20 March 2017 – Statin use decreases the risk of decompensation and mortality in patients with cirrhosis due to hepatitis C virus (HCV). Whether this beneficial effect can be extended to cirrhosis in the general population or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains unknown. Statin use also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV and HCV infection.
LiverLearning®: 2017 Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver Disease
The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge and treatment options in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered although no established treatment has been approved. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic that threatens our quality of life.Zobair M. Younossi Zobair M.
Down‐regulation of hepatocyte nuclear factor‐4α and defective zonation in livers expressing mutant Z α1‐antitrypsin
Pasquale Piccolo, Patrizia Annunziata, Leandro R. Soria, Sergio Attanasio, Anna Barbato, Raffaele Castello, Annamaria Carissimo, Luca Quagliata, Luigi M. Terracciano, Nicola Brunetti‐Pierri – 15 March 2017 – α1‐Antitrypsin (AAT) deficiency is one of the most common genetic disorders and the liver disease due to the Z mutant of AAT (ATZ) is a prototype of conformational disorder due to protein misfolding with consequent aberrant intermolecular protein aggregation.